Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
LXLexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. (LXEO)

NASDAQ Global Market · Currency in USD
$2.80 ▼ -0.09 (-3.11%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.80 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$2.89
Open
$2.87
Day's Range
$2.73 – $2.90
52 Week Range
$2.55 – $10.99
Volume
619,381
Avg. Volume
1,201,965
Market Cap
$229.85M
Beta (5Y Monthly)
1.64
PE Ratio (TTM)
--
EPS (TTM)
-$1.02
Earnings Date
Dec 14, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$21.13

Profile: Lexeo Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
63
CEO
R. Nolan Townsend

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations.

Earnings

Next report: Mon, Dec 14, 2026
EPS estimate -$0.32
DateEst.Actual
Aug 12, 2026-$0.29-$0.30Miss
May 11, 2026-$0.29-$0.25Beat
Mar 30, 2026-$0.32-$0.27Beat
Nov 5, 2025-$0.48-$0.33Beat
Aug 14, 2025-$0.64-$0.60Beat
May 12, 2025-$0.80-$0.99Miss

Analyst view

Consensus price target
$21.13 ▲ +654.6%
Range $10.00 – $30.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on LXEO and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.